1
|
Caterino M, De Felice M, Poliero L, Mazzarella G, Pirozzi M, Facchini S, Ciardiello F, Fasano M. Is there a role for adjuvant therapy in radiation-induced angiosarcoma of the breast? A case report and review of the literature. Eur Rev Med Pharmacol Sci 2023; 27:4169-4174. [PMID: 37203843 DOI: 10.26355/eurrev_202305_32326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
BACKGROUND Angiosarcoma (AS) of the breast is very rare, accounting for 1% of all soft tissue breast tumors. AS may present as primary tumors of the breast or as secondary lesions usually associated with previous radiotherapy. Commonly, secondary AS affects older women (median age 67-71 years) with a clinical history of breast cancer. The preferred site of onset of RIAS is the edge of radiation fields, where radiation doses and tumor necrosis may be heterogeneous, resulting in a DNA damage and instability. Radical surgery is the treatment of choice, but no clear consensus exists on surgical management of breast AS. CASE REPORT We describe an atypical case of relapsed RIAS after radical mastectomy, treated with new surgery and, considering the higher risk of recurrence, subsequent adjuvant chemotherapy with weekly paclitaxel. CONCLUSIONS The frequency of radiation-induced angiosarcomas (RIAS) after breast-conserving surgery and radiotherapy has been increased to 0.14-0.5% among long survivors. Nevertheless, even if RIAS continues to be prognostically an extremely unfavorable cancer due to a high rate of recurrence, distant spread, and median overall survival (OS) of about 60 months, the benefits of loco-regional breast radiotherapy are clearly higher than the risk in developing angiosarcoma.
Collapse
Affiliation(s)
- M Caterino
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
D'Aniello C, Cavaliere C, Foglia C, Facchini S, Uricchio F, Balsamo R, Franzese E, De Falco S, Izzo M, Laterza M, Liguori C, Coppola P, Diessa Y, Fasano M, Di Lauro G, Lai S, Cocetta V, Pisconti S, Montesarchio V, Facchini G. Management of systemic prostate cancer: current algorithm from castration sensitive to castration resistant setting. Eur Rev Med Pharmacol Sci 2022; 26:8481-8501. [PMID: 36459030 DOI: 10.26355/eurrev_202211_30384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
In recent years, the advanced knowledge of clinical, biological and molecular features of prostate cancer have led to the introduction of new drugs and have allowed the relocation of old drugs in different settings. In this way, the new concepts of systemic disease arise: high risk or high volume vs. low risk and low volume disease castration sensitive prostate cancer (CSPC), diversifying the use of previously approved drugs (CRPC) and opening new scenarios for sequence therapy. The aim of this review is to integrate new developments into the medical management of systemic prostate cancer.
Collapse
Affiliation(s)
- C D'Aniello
- Division of Medical Oncology, AORN dei Colli Ospedali Monaldi-Cotugno-CTO, Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Monti M, Fasano M, Palandri L, Righi E. A review of European and international phthalates regulation: focus on daily use products. Eur J Public Health 2022; 32:ckac131.226. [PMCID: PMC9594424 DOI: 10.1093/eurpub/ckac131.226] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2023] Open
Abstract
Background Phthalates are known endocrine disruptors used in a wide range of industrial and household products. With globalization and interdependency of the supply chain, the control of toxic substances in daily use products has become more challenging. Many countries have implemented laws and policies to limit their use, although these regulations are neither unified nor seem adequate, as studies suggest that more vulnerable populations (children, pregnant women) are exposed to phthalates that should be restricted. Methods For seven of the most used phthalates - bis(2-Ethylhexyl) phthalate (DEHP), Butylbenzyl phthalate (BBP), Dibutyl phthalate (DBP), Diisobutyl phthalate (DIBP), diisononyl phthalate (DINP), diisodecyl phthalate (DIDP), Di-n-octyl phthalate (DNOP) - we performed an online research on institutional sites and dedicated Agencies of the three largest world economies (European Union (EU), United States of America (USA), China) to analyze their uses and bans, focusing on Food Contacts Materials (FCM), cosmetics, toys and childcare articles. Results In the EU area DEHP, BBP, DBP and DIBP are not allowed in toys and childcare articles above 0,1% by weight. All the seven phthalates are also severely restricted in FCM, and mostly banned as cosmetic components. In the USA, there is no formal prohibition to their use in cosmetics but phthalates are mostly limited in FCM. In China, the limit for DBP, BBP, DEHP, DNOP, DINP, DIDP in plastic toys is 0,1% of the material composition; regarding cosmetics DEHP, BBP and DBP are prohibited. Conclusions We found substantial differences in the international legislation. Though there is essential agreement on toys and childcare articles legislation, there are many discrepancies about FCM and cosmetics. Further research is needed to compare the regulation with data about concentrations of these ubiquitous elements, to underline the real exposure and risk in different populations and to improve knowledge and safety on this matter. Key messages • Phthalates, known endocrine disruptors, in daily use products are a matter of concern. • Coordinated international laws to prevent exposure, especially in vulnerable populations, are needed.
Collapse
Affiliation(s)
- M Monti
- Postgraduate School of Public Health, University of Modena and Reggio Emilia, Modena, Italy
| | - M Fasano
- Postgraduate School of Public Health, University of Modena and Reggio Emilia, Modena, Italy
| | - L Palandri
- Postgraduate School of Public Health, University of Modena and Reggio Emilia, Modena, Italy
| | - E Righi
- Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
4
|
Della Corte C, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay C, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F. 163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Fasano M, Pirozzi M, Zotta A, Caterino M, Facchini S, Messina G, Rinaldi L. Diagnostic performance of LI-RADS in adult patients with rare hepatic tumors. Eur Rev Med Pharmacol Sci 2022; 26:736-739. [PMID: 35179737 DOI: 10.26355/eurrev_202202_27979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- M Fasano
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
| | | | | | | | | | | | | |
Collapse
|
6
|
Rinaldi B, Rosato V, Galiero R, Vetrano E, Fasano M, Rinaldi L. Editorial - Direct-acting antivirals therapy in HCV patients with HCC: lights and shadow. Eur Rev Med Pharmacol Sci 2021; 25:7622-7625. [PMID: 34982423 DOI: 10.26355/eurrev_202112_27608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- B Rinaldi
- Department of Experimental Medicine, Section of Pharmacology, University of Campania Luigi Vanvitelli, Naples, Italy.
| | | | | | | | | | | |
Collapse
|
7
|
Abstract
The diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection relies on the detection of viral RNA by real-time reverse transcription polymerase chain reaction (rRT-PCR) performed with respiratory specimens, especially nasopharyngeal swabs. However, this procedure requires specialized medical personnel, centralized laboratory facilities, and time to provide results (from several hours up to 1 d). In addition, there is a non-negligible risk of viral transmission for the operator who performs the procedure. For these reasons, several studies have suggested the use of other body fluids, including saliva, for the detection of SARS-CoV-2. The use of saliva as a diagnostic specimen has numerous advantages: it is easily self-collected by the patient with almost no discomfort, it does not require specialized health care personnel for its management, and it reduces the risks for the operator. In the past few months, several scientific papers, media, and companies have announced the development of new salivary tests to detect SARS-CoV-2 infection. Posterior oropharyngeal saliva should be distinguished from oral saliva, since the former is a part of respiratory secretions, while the latter is produced by the salivary glands, which are outside the respiratory tract. Saliva can be analyzed through standard (rRT-PCR) or rapid molecular biology tests (direct rRT-PCR without extraction), although, in a hospital setting, these procedures may be performed only in addition to nasopharyngeal swabs to minimize the incidence of false-negative results. Conversely, the promising role of saliva in the diagnosis of SARS-CoV-2 infection is highlighted by the emergence of point-of-care technologies and, most important, point-of-need devices. Indeed, these devices can be directly used in workplaces, airports, schools, cinemas, and shopping centers. An example is the recently described Rapid Salivary Test, an antigen test based on the lateral flow assay, which detects the presence of the virus by identifying the spike protein in the saliva within a few minutes.
Collapse
Affiliation(s)
- L. Azzi
- Unit of Oral Medicine and
Pathology, ASST dei Sette Laghi–Ospedale di Circolo e Fondazione Macchi,
Department of Medicine and Surgery, University of Insubria, Varese,
Italy
| | - V. Maurino
- Unit of Oral Medicine and
Pathology, ASST dei Sette Laghi–Ospedale di Circolo e Fondazione Macchi,
Department of Medicine and Surgery, University of Insubria, Varese,
Italy
| | - A. Baj
- Laboratory of Clinical
Microbiology, ASST dei Sette Laghi–Ospedale di Circolo e Fondazione Macchi,
Department of Medicine and Surgery, University of Insubria, Varese,
Italy
| | - M. Dani
- Unit of Oral Medicine and
Pathology, ASST dei Sette Laghi–Ospedale di Circolo e Fondazione Macchi,
Department of Medicine and Surgery, University of Insubria, Varese,
Italy
| | - A. d’Aiuto
- Unit of Oral Medicine and
Pathology, ASST dei Sette Laghi–Ospedale di Circolo e Fondazione Macchi,
Department of Medicine and Surgery, University of Insubria, Varese,
Italy
| | - M. Fasano
- Laboratory of Biochemistry and
Functional Proteomics, Department of Science and High Technology, Busto
Arsizio (VA), Italy
| | - M. Lualdi
- Laboratory of Biochemistry and
Functional Proteomics, Department of Science and High Technology, Busto
Arsizio (VA), Italy
| | - F. Sessa
- Unit of Pathology, ASST dei Sette
Laghi–Ospedale di Circolo e Fondazione Macchi, Department of Medicine and
Surgery, University of Insubria, Varese, Italy
| | - T. Alberio
- Laboratory of Biochemistry and
Functional Proteomics, Department of Science and High Technology, Busto
Arsizio (VA), Italy
| |
Collapse
|
8
|
Fasano M, Della Corte C, Di Liello R, Barra G, Cimmino F, Sparano F, Viscardi G, Iacovino M, Paragliola F, Famiglietti V, Ciaramella V, Sforza V, Morabito A, Maiello E, Ciardiello F, Morgillo F. 1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Viscardi G, Sparano F, Di Liello R, Casal GA, Ferreres RB, Bruixola G, Gambardella V, Zanaletti N, Iacovino M, De Corte CM, Papaccio F, Fasano M, Ciardiello F, Cervantes A, Morgillo F, Martorell PM, Molla MAI. A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz449.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Sparano F, Barra G, Della Corte C, Di Liello R, Fasano M, Ciardiello F, Morgillo F. Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Wunschel J, Fasano M, Ford B, Porterfield H. OXYPORUS: A POTENTIAL EMERGING PATHOGEN IN CHRONIC GRANULOMATOUS DISEASE PATIENTS. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Gencay M, Seffner A, Pabinger S, Gautier J, Gohl P, Weizenegger M, Neofytos D, Batrla R, Woeste A, Kim HS, Westergaard G, Reinsch C, Brill E, Thuy PTT, Hoang BH, Sonderup M, Spearman CW, Brancaccio G, Fasano M, Gaeta GB, Santantonio T, Kaminski WE. Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays. J Viral Hepat 2018; 25:1132-1138. [PMID: 29660206 DOI: 10.1111/jvh.12915] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 03/25/2018] [Indexed: 12/12/2022]
Abstract
An important requirement for a state-of-the-art hepatitis B surface antigen (HBsAg) screening assay is reliable detection of mutated HBsAg. Currently, there is a striking shortage of data regarding the detection rates of in vivo HBsAg mutations for these clinically important assays. Therefore, we compared the detection rates of four commercial HBsAg screening assays using a global cohort of 1553 patients from four continents with known HBV genotypes. These samples, which represent the broadest spectrum of known and novel HBsAg major hydrophilic region (MHR) mutations to date, were analyzed for the presence of HBsAg using the Roche Elecsys® HBsAg II Qualitative, Siemens ADVIA Centaur XP HBsAg II, Abbott Architect HBsAg Qualitative II and DiaSorin Liaison® HBsAg Qualitative assays, respectively. Of the 1553 samples, 1391 samples could be sequenced; of these, 1013 (72.8%) carried at least one of the 345 currently known amino acid substitutions (distinct HBsAg mutation) in the HBsAg MHR. All 1553 patient samples were positive for HBsAg using the Elecsys® HBsAg II Qual assay, with a sensitivity (95% confidence interval) of 99.94% (99.64%-100%), followed by the Abbott Architect 99.81% (99.44%-99.96%), Siemens ADVIA 99.81% (99.44%-99.96%) and DiaSorin Liaison® 99.36% (98.82%-99.69%) assays, respectively. Our results indicate that the Elecsys® HBsAg II Qual assay exhibits the highest sensitivity among the commercial HBsAg screening assays, and demonstrate that its capacity to detect HBV infection is not compromised by HBsAg MHR mutants.
Collapse
Affiliation(s)
- M Gencay
- Roche Diagnostics International Ltd, Rotkreuz, Switzerland
| | - A Seffner
- Department of Molecular Genetics and Microbiology, MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany
| | - S Pabinger
- Health and Environment Department, Molecular Diagnostics, Austrian Institute of Technology, Vienna, Austria
| | - J Gautier
- Cerba Spécimen Services, Saint-Ouen l'Aumône, France
| | - P Gohl
- Bioscientia, Institute for Medical Diagnostics GmbH, Ingelheim, Germany
| | - M Weizenegger
- Department of Molecular Genetics and Microbiology, MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany
| | - D Neofytos
- Roche Diagnostics International Ltd, Rotkreuz, Switzerland
| | - R Batrla
- Roche Diagnostics International Ltd, Rotkreuz, Switzerland
| | - A Woeste
- Roche Diagnostics GmbH, Penzberg, Germany
| | - H S Kim
- Department of Laboratory Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea
| | - G Westergaard
- Roche Diagnostics International Ltd, Rotkreuz, Switzerland
| | - C Reinsch
- Roche Diagnostics GmbH, Mannheim, Germany
| | - E Brill
- Bioscientia, Institute for Medical Diagnostics GmbH, Ingelheim, Germany
| | - P T T Thuy
- Hepatology Department, Medic Medical Center, Ho Chi Minh City, Vietnam
| | - B H Hoang
- Gastroenterology Department, Ho Chi Minh City University Medical Center, Ho Chi Minh City, Vietnam
| | - M Sonderup
- Division of Hepatology and Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - C W Spearman
- Division of Hepatology and Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | - G Brancaccio
- Infectious Diseases and Viral Hepatitis Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | - M Fasano
- Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - G B Gaeta
- Infectious Diseases and Viral Hepatitis Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | - T Santantonio
- Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - W E Kaminski
- Bioscientia, Institute for Medical Diagnostics GmbH, Ingelheim, Germany
| |
Collapse
|
13
|
Della Corte C, Barra G, Ciaramella V, Di Liello R, Fasano M, Ciardiello F, Morgillo F. The combination of MEK inhibitor and anti PD-L1: Effects on organoid models from NSCLC biopsies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Di Liello R, Viscardi G, Ciaramella V, Barra G, Esposito G, Fasano M, Ciardiello F, Morgillo F. Role of pioglitazone on gene/protein expression profile, bioenergetics and TGFβ/SMAD signaling pathway in NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Caraballo J, Fasano M, Russi AS. P269 Immunological phenotype of a patient with mandibulofacial dysostosis Guion-Almeida type with novel ETFUD2 splicing variant. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Perez-Montero H, Bonel AC, Fasano M, Pedraza S, Guardado S, Mendoza AC, Gascon N, Asiain L, Nenclares P, Sanz A, Dura J, Mera A, Perez-Escutia M, Bartolome A, Perez-Regadera J, Castellano D, Villacampa F, Cabeza M. Long-Term Outcomes of Organ Preservation for Bladder Cancer in a Large Cohort. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Morciano M, Fasano M, Nold A, Braga C, Yatsyshin P, Sibley DN, Goddard BD, Chiavazzo E, Asinari P, Kalliadasis S. Nonequilibrium molecular dynamics simulations of nanoconfined fluids at solid-liquid interfaces. J Chem Phys 2017; 146:244507. [DOI: 10.1063/1.4986904] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Affiliation(s)
- M. Morciano
- Energy Department, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino 10129, Italy
| | - M. Fasano
- Energy Department, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino 10129, Italy
| | - A. Nold
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| | - C. Braga
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| | - P. Yatsyshin
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| | - D. N. Sibley
- Department of Mathematical Sciences, Loughborough University, Loughborough LE11 3TU, United Kingdom
| | - B. D. Goddard
- The School of Mathematics and Maxwell Institute for Mathematical Sciences, The University of Edinburgh, Edinburgh EH9 3JZ, United Kingdom
| | - E. Chiavazzo
- Energy Department, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino 10129, Italy
| | - P. Asinari
- Energy Department, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino 10129, Italy
| | - S. Kalliadasis
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| |
Collapse
|
18
|
Esposito G, Corte CD, Papaccio F, Viscardi G, Fasano M, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Efficacy of osimertinib in combination with Hedgehog pathway inhibitors in reverting T790M-mediated resistence. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Savastano B, Corte CD, Papaccio F, Giuseppe V, Esposito G, Fasano M, Orditura M, De Vita F, Ciardiello F, Morgillo F. Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Papaccio F, Corte CD, Viscardi G, Esposito G, Fasano M, De Vita F, Orditura M, Ciardiello F, Morgillo F. Efficacy of second and third generation EGFR tyrosine kinase inhibitors, alone or in combination, in T790M-mediated resistance. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Fiore F, Gargiulo L, Cardone C, Laterza M, Fasano M, De Vita F, Ciardiello F. Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of the Second University of Naples (SUN). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw386.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Ciaramella V, Corte CD, Papaccio F, Giuseppe V, Esposito G, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. New insights from KISS activity: a prognostic biomarker in malignant pleural mesothelioma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw392.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Corte CD, Papaccio F, Viscardi G, Esposito G, Fasano M, Castellone M, Parascandolo A, De Vita F, Orditura M, Ciardiello F, Morgillo F. Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Viscardi G, Corte CD, Papaccio F, Esposito G, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Fiore F, Gargiulo L, Cardone C, Laterza M, Fasano M, De Vita F, Ciardiello F. Evaluation of burnout syndrome and personalized intervention in the medical oncology unit of second university of naples (sun). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw342.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, Pittaluga F, Coppola N, Wedemeyer H, Zachou K, Marrone A, Fasano M, Lotti G, Andreone P, Iacobellis A, Andriulli A, Rizzetto M. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Ther 2016; 44:620-8. [PMID: 27443972 DOI: 10.1111/apt.13734] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 05/10/2016] [Accepted: 06/27/2016] [Indexed: 12/12/2022]
Abstract
BACKGROUND Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point is disputed. AIM To assess the role of serum hepatitis B surface antigen (HBsAg) in the clearance of HDV-RNA in pegylated interferon (Peg-IFN)-treated chronic hepatitis D (CHD). METHODS Sixty-two patients with CHD, treated with Peg-IFN, were considered. The patients belonged to three groups: 14 patients cleared the HBsAg and HDV-RNA (responders, R), 12 cleared the HDV-RNA remaining positive for HBsAg (partial responders, PR) and 36 cleared neither the HBsAg nor the HDV-RNA (nonresponders, NR). RESULTS In responders, at baseline the median value (mv) of HBsAg and HDV-RNA was 1187 and 188 663 IU/mL. By month 6 of therapy, HBsAg declined to less than 1000 IU/mL and HDV-RNA was undetectable in 12 patients. In NR, the pre-therapy median value of HBsAg and HDV viremia was 6577 and 676 319 IU/mL. There was no significant reduction of antigen at month 6; after a decline, HDV-RNA rebounded to baseline levels. In PR, the median value of baseline HBsAg was 7031 IU/mL; it declined at month 6 in the majority. HDV-RNA progressively declined from an initial median value of 171 405 IU/mL. HBsAg <1000 IU/mL at month 6 discriminated responders and PR from NR (P < 0.001). By ROC curve, the threshold of 0.105 log reduction of HBsAg associated with 1.610 log reduction of HDV-RNA from baseline to month 6 predicted the clearance of this marker. CONCLUSIONS A reduction of serum HBsAg is mandatory for the definitive clearance of the HDV-RNA. Quantitative HBsAg may predict the long-term response to Peg-IFN therapy and provide a guide to prolong or stop treatment.
Collapse
Affiliation(s)
- G A Niro
- Gastroenterology Unit, IRCCS 'Casa Sollievo Sofferenza' Hospital, San Giovanni Rotondo (FG), Italy
| | - A Smedile
- Department of Medical Sciences University of Turin, Division of Gastroenterology and Hepatology, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - R Fontana
- Gastroenterology Unit, IRCCS 'Casa Sollievo Sofferenza' Hospital, San Giovanni Rotondo (FG), Italy
| | - A Olivero
- Department of Medical Sciences University of Turin, Division of Gastroenterology and Hepatology, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - A Ciancio
- Department of Medical Sciences University of Turin, Division of Gastroenterology and Hepatology, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - M R Valvano
- Gastroenterology Unit, IRCCS 'Casa Sollievo Sofferenza' Hospital, San Giovanni Rotondo (FG), Italy
| | - F Pittaluga
- Microbiology and Virology Unit, A.O. Città della Salute e della Scienza, Molinette Hospital, University of Turin, Turin, Italy
| | - N Coppola
- Department of Mental Health and Public Medicine, Second University of Naples, Caserta, Italy
| | - H Wedemeyer
- Department for Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, German Center for Infection Research, Hannover, Germany
| | - K Zachou
- Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa, Greece
| | - A Marrone
- Internal Medicine and Hepatology, Second University of Naples, Italy
| | - M Fasano
- Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - G Lotti
- IRCCS 'Casa Sollievo Sofferenza' Hospital, Blood Bank, San Giovanni Rotondo (FG), Italy
| | - P Andreone
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - A Iacobellis
- Gastroenterology Unit, IRCCS 'Casa Sollievo Sofferenza' Hospital, San Giovanni Rotondo (FG), Italy
| | - A Andriulli
- Gastroenterology Unit, IRCCS 'Casa Sollievo Sofferenza' Hospital, San Giovanni Rotondo (FG), Italy
| | - M Rizzetto
- Department of Medical Sciences University of Turin, Division of Gastroenterology and Hepatology, Città della Salute e della Scienza University Hospital, Turin, Italy
| |
Collapse
|
27
|
Fasano M, Della Corte C, Papaccio F, Viscardi G, Esposito G, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Results of safety run-in part in Metal (METformin in Advanced Lung cancer) trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Affiliation(s)
- P Ascenzi
- Interdepartmental Laboratory for Electron Microscopy, Roma Tre University, Roma I-00146, Italy
| | - A di Masi
- Interdepartmental Laboratory for Electron Microscopy, Roma Tre University, Roma I-00146, Italy.,Department of Sciences, Roma Tre University, Roma I-00146, Italy
| | - G Fanali
- Department of Theoretical and Applied Sciences, Biomedical Research Division, University of Insubria, Busto Arsizio I-21052, Italy
| | - M Fasano
- Department of Theoretical and Applied Sciences, Biomedical Research Division, University of Insubria, Busto Arsizio I-21052, Italy.,Center of Neuroscience, University of Insubria, Busto Arsizio I-21052, Italy
| |
Collapse
|
29
|
Abstract
Human serum albumin (HSA): (i) controls the plasma oncotic pressure, (ii) modulates fluid distribution between the body compartments, (iii) represents the depot and carrier of endogenous and exogenous compounds, (iv) increases the apparent solubility and lifetime of hydrophobic compounds, (v) affects pharmacokinetics of many drugs, (vi) inactivates toxic compounds, (vii) induces chemical modifications of some ligands, (viii) displays antioxidant properties, and (ix) shows enzymatic properties. Under physiological and pathological conditions, HSA has a pivotal role in heme scavenging transferring the metal-macrocycle from high- and low-density lipoproteins to hemopexin, thus acquiring globin-like reactivity. Here, the heme-based catalytic properties of HSA are reviewed and the structural bases of drug-dependent allosteric regulation are highlighted.
Collapse
Affiliation(s)
- P Ascenzi
- Interdepartmental Laboratory for Electron Microscopy, Roma Tre University , 00146 Roma, Italy
| | - A di Masi
- Interdepartmental Laboratory for Electron Microscopy, Roma Tre University, 00146 Roma, Italy; Department of Sciences, Roma Tre University, 00146 Roma, Italy
| | - G Fanali
- Biomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria , 21052 Busto Arsizio, Italy
| | - M Fasano
- Biomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria, 21052 Busto Arsizio, Italy; Center of Neuroscience, University of Insubria, 21052 Busto Arsizio, Italy
| |
Collapse
|
30
|
Andriulli A, Morisco F, Ippolito AM, Di Marco V, Valvano MR, Angelico M, Fattovich G, Granata R, Smedile A, Milella M, Felder M, Gaeta GB, Gatti P, Fasano M, Mazzella G, Santantonio T. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int 2015; 9:52-7. [PMID: 25788379 DOI: 10.1007/s12072-014-9556-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 06/21/2014] [Indexed: 01/06/2023]
Abstract
AIM To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA). PATIENTS AND METHODS A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13%) with subtype 1a and 1,074 (87%) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype. RESULTS At multivariate analysis, baseline characteristics differentiating patients with HCV-1a versus HCV-1b were young age, male gender, no F4 fibrosis, and no diabetes. SVR was achieved by 37% of patients with subtype 1b and 45% of those with subtype 1a, a nonsignificant difference of 8% (p = 0.069). In patients with subtype 1a, predictors of SVR were IL28B CC (OR 5.78, CI 1.98-16.83), RVR (OR 4.18, CI 1.66-10.55), female gender (OR 2.83, CI 1.83-6.78), and HCVRNA (OR 0.55, CI 0.32-0.96). In patients with subtype 1b, the ranking of predictors was levels RVR (OR 6.49, CI 4.32-9.73), IL28B CC (OR 3.32, CI 2.15-4.58), γGT (OR 1.59, CI 0.14-2.22), HCVRNA (OR 0.61, CI 0.47-0.79), and age (OR 0.01, CI 0.02-0.42). CONCLUSION In Italy HCV-1 subtype 1a prevails in young male patients with less advanced liver damage, findings that imply a more recent spreading of the infection with this viral strain. The two HCV-1 subtypes appear equally responsive to Peg-IFN/RIBA, with IL28B genotyping and monitoring of RVR mostly influencing the therapeutic response.
Collapse
Affiliation(s)
- A Andriulli
- Division of Gastroenterology, Casa Sollievo Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Della Corte C, Fasano M, Vitagliano D, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Role of Hedgehog Pathway in Mediating Resistance to Egfr-Inhibitors in Non-Small Cell Lung Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Morgillo F, Della Corte C, Vitagliano D, Fasano M, Troiani T, Martinelli E, Ciardiello F. Co-Activation of Hedgehog and Met Pathways in Mediating Resistance to Gefitinib in Non-Small Cell Lung Cancer Cell Line Harboring Activating Mutation of Egfr. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Sagnelli E, Santantonio T, Coppola N, Fasano M, Pisaturo M, Sagnelli C. Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. Infection 2014; 42:601-10. [DOI: 10.1007/s15010-014-0608-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Accepted: 02/24/2014] [Indexed: 02/06/2023]
|
34
|
Fasano M, Saracino A, Carosi G, Mazzotta F, Marino N, Sagnelli E, Gaeta GB, Angarano G, Verucchi G, Bellissima P, Angeletti C, Santantonio T. Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study. Infection 2013. [PMID: 23264094 DOI: 10.1007/s15010-012-0384-9]] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND The continuing migration of individuals from geographic areas with high/medium endemicity has determined the arrival of new chronic hepatitis B virus (HBV) carriers in Italy. The magnitude of this phenomenon and clinical/virological features of HBsAg-positive migrants remain not very well defined. AIMS To evaluate the proportion of HBsAg-positive immigrants enrolled in this multicenter Società Italiana di Malattie Infettive e Tropicali (SIMIT) cross-sectional study and to compare the characteristics of chronic hepatitis B infection in migrants to those of Italian carriers. METHODS From February 1 to July 31 2008, anonymous data were obtained from all HBsAg-positive patients aged ≥ 18 years observed at 74 Italian centers of infectious diseases. RESULTS Of the 3,760 HBsAg-positive subjects enrolled, 932 (24.8 %) were immigrants, with a prevalent distribution in central to northern Italy. The areas of origin were: Far East (37.1 %), Eastern Europe (35.4 %), Sub-Saharan Africa (17.5 %), North Africa (5.5 %), and 4.5 % from various other sites. Compared to Italian carriers, migrants were significantly younger (median age 34 vs. 52 years), predominantly female (57.5 vs. 31 %), and most often at first observation (incident cases 34.2 vs. 13.3 %). HBeAg-positives were more frequent among migrants (27.5 vs. 14 %). Genotype D, found in 87.8 % of Italian carriers, was present in only 40 % of migrants, who were more frequently inactive HBV carriers, with a lower prevalence of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Only 27.1 % of migrants received antiviral treatment compared to 50.3 % of Italians. CONCLUSIONS Twenty-five percent of all HBV carriers examined at Italian centers was composed of immigrants with demographic, serological, and virological characteristics that differed from those of natives and appeared to have an inferior access to treatment.
Collapse
Affiliation(s)
- M Fasano
- Clinic of Infectious Diseases, University of Bari, Bari, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Fasano M, Saracino A, Carosi G, Mazzotta F, Marino N, Sagnelli E, Gaeta GB, Angarano G, Verucchi G, Bellissima P, Angeletti C, Santantonio T. Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study. Infection 2012; 41:53-9. [PMID: 23264094 DOI: 10.1007/s15010-012-0384-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2012] [Accepted: 12/07/2012] [Indexed: 12/17/2022]
Abstract
BACKGROUND The continuing migration of individuals from geographic areas with high/medium endemicity has determined the arrival of new chronic hepatitis B virus (HBV) carriers in Italy. The magnitude of this phenomenon and clinical/virological features of HBsAg-positive migrants remain not very well defined. AIMS To evaluate the proportion of HBsAg-positive immigrants enrolled in this multicenter Società Italiana di Malattie Infettive e Tropicali (SIMIT) cross-sectional study and to compare the characteristics of chronic hepatitis B infection in migrants to those of Italian carriers. METHODS From February 1 to July 31 2008, anonymous data were obtained from all HBsAg-positive patients aged ≥ 18 years observed at 74 Italian centers of infectious diseases. RESULTS Of the 3,760 HBsAg-positive subjects enrolled, 932 (24.8 %) were immigrants, with a prevalent distribution in central to northern Italy. The areas of origin were: Far East (37.1 %), Eastern Europe (35.4 %), Sub-Saharan Africa (17.5 %), North Africa (5.5 %), and 4.5 % from various other sites. Compared to Italian carriers, migrants were significantly younger (median age 34 vs. 52 years), predominantly female (57.5 vs. 31 %), and most often at first observation (incident cases 34.2 vs. 13.3 %). HBeAg-positives were more frequent among migrants (27.5 vs. 14 %). Genotype D, found in 87.8 % of Italian carriers, was present in only 40 % of migrants, who were more frequently inactive HBV carriers, with a lower prevalence of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Only 27.1 % of migrants received antiviral treatment compared to 50.3 % of Italians. CONCLUSIONS Twenty-five percent of all HBV carriers examined at Italian centers was composed of immigrants with demographic, serological, and virological characteristics that differed from those of natives and appeared to have an inferior access to treatment.
Collapse
Affiliation(s)
- M Fasano
- Clinic of Infectious Diseases, University of Bari, Bari, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Scagnolari C, Trombetti S, Soldà A, Milella M, Gaeta G, Angarano G, Scotto G, Caporaso N, Morisco F, Cozzolongo R, Giannelli G, Fasano M, Santantonio T, Antonelli G. Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α. Clin Microbiol Infect 2012; 18:1033-9. [DOI: 10.1111/j.1469-0691.2011.03729.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
37
|
Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M, Ciardiello F. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011; 22:1528-1534. [PMID: 21212155 DOI: 10.1093/annonc/mdq630] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Sorafenib is a small-molecule multitargeted kinase inhibitor that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, vascular endothelial growth factor receptor 2 (VEGFR-2), VEGFR-3 and platelet-derived growth factor receptor β. The aim of this multicenter, randomized phase II study was to evaluate clinical activity and safety of sorafenib in combination with erlotinib or gemcitabine in unselected untreated elderly patients with non-small-cell lung cancer (NSCLC). METHODS The trial was designed to select the most promising sorafenib-containing combination in previously untreated elderly (≥70 years) stage IIIB or IV NSCLC patients, with performance status of zero to two. Patients were randomly assigned to one of the following combinations: gemcitabine, 1200 mg/m(2) days 1 and 8, every 21 days, for a maximum of six cycles, plus sorafenib, 800 mg/day, until disease progression or unacceptable toxicity (arm 1); or erlotinib, 150 mg/day, plus sorafenib, 800 mg/day, until disease progression or unacceptable toxicity (arm 2). A selection design was applied with 1-year survival rate as the primary end point of the study, requiring 58 patients. RESULTS Sixty patients were randomly allocated to the study (31 patients in arm 1 and 29 patients in arm 2). After a median follow-up of 15 months, 10 patients [32%, 95% confidence interval (CI) 16% to 49%] in arm 1 and 13 patients (45%, 95% CI 27% to 63%) in arm 2 were alive at 1 year. Median overall survival was 6.6 and 12.6 months in arm 1 and arm 2, respectively. Observed toxic effects were consistent with the expected drug profiles. CONCLUSIONS The combination of erlotinib and sorafenib was feasible in elderly patients with advanced NSCLC and was associated with a higher 1-year survival rate than the other arm. According to the selection design, this combination warrants further investigation in phase III trials.
Collapse
Affiliation(s)
- C Gridelli
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino
| | - F Morgillo
- Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples
| | - A Favaretto
- Division of Medical Oncology II, Istituto Oncologico Veneto, Padua
| | - F de Marinis
- Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo Hospital, Rome
| | - A Chella
- Pulmonary Unit, University Hospital of Pisa, Pisa
| | - G Cerea
- The Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milan
| | - R Mattioli
- Medical Oncology Unit, S. Croce Hospital, Fano
| | - G Tortora
- Medical Oncology Unit, Department of Molecular and Clinical Endocrinology, University of Naples "Federico II"
| | - A Rossi
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino
| | - M Fasano
- Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples
| | - G Pasello
- Division of Medical Oncology II, Istituto Oncologico Veneto, Padua
| | - S Ricciardi
- Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo Hospital, Rome
| | - P Maione
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino
| | - M Di Maio
- Clinical Trials Unit, National Cancer Institute, Naples, Italy
| | - F Ciardiello
- Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples.
| |
Collapse
|
38
|
Aurilio G, Ricci V, De Vita F, Fasano M, Fazio N, Orditura M, Funicelli L, De Luca G, Iasevoli D, Iovino F, Ciardiello F, Conzo G, Nolè F, Lamendola M. A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). Ecancermedicalscience 2010; 4:197. [PMID: 22276042 PMCID: PMC3234019 DOI: 10.3332/ecancer.2010.197] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Indexed: 12/22/2022] Open
Abstract
Lymphoepithelial carcinoma is an undifferentiated nasopharyngeal carcinoma with lymphoid stroma and non-keratinizing squamous cells with distinctive clinical, epidemiological and etiological features. Conversely, lymphoepithelioma-like carcinomas (LELCs) are carcinomas that arise outside the nasopharynx but resemble a lymphoepithelioma histologically. In this case study, LELC presentation in connective tissue (left sternocleidomastoid muscle) is peculiar and unusual, but its diagnosis is supported by histological findings and clinical history, especially long disease free survival and no primary lesions in nasopharynx and lung district. We also discuss the pathogenesis, hypothesizing an embryological theory. To our knowledge, it could be the first reported case of a primary connective tissue LELC to the neck.
Collapse
Affiliation(s)
- G Aurilio
- Medical Care Unit, Department of Medical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Alberio T, Fasano M. Proteome chemistry to understand molecular bases of neurodegenerative disorders. J Biotechnol 2010. [DOI: 10.1016/j.jbiotec.2010.08.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Fasano M, Greco MA. Proliferative Activity of Adrenal Glands with Adrenocortical Cytomegaly Measured by MIB-1 Labeling Index. ACTA ACUST UNITED AC 2010. [DOI: 10.1080/15513819609169303] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
41
|
Willems P, Magri V, Cretnik M, Fasano M, Jakubowska A, Levanat S, Lubinski J, Marras E, Musani V, Thierens H, Vandersickel V, Perletti G, Vral A. Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg). Int J Oncol 2009; 34:1005-15. [PMID: 19287957 DOI: 10.3892/ijo_00000226] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In the Milan area (Northern Italy), we identified a family characterized by a high prevalence of ovarian and breast cancer cases (5 out of 6 subjects, over 3 generations), and a predominant prevalence of ovarian lesions (4 out of 5 patients). Analysis of BRCA1 and BRCA2 genes allowed the identification of the missense c.190T>C mutation in codon 64 (Cys64Arg) of BRCA1. The aims of the present investigation were to characterize the functional implications of the c.190T>C mutation at the molecular level, and to search whether additional polymorphisms might be linked to the peculiar phenotypic features observed in the Italian pedigree. Molecular modelling studies suggested that substitution of the cysteine 64 with an arginine likely disrupts the architecture of the BRCA1 RING finger domain, responsible for the interaction with BARD1, essential for the tumor-suppressor activity of the BRCA1-BARD1 complex. By splicing site information analysis, exonic splicing enhancer site characterization, and analysis of transcript fragment length and sequence, we showed that the c.190T>C mutation was able to modulate the splicing of exon 5 in a fashion opposite to the c.190T>G transversion, responsible for the functionally-related Cys64Gly amino acid substitution. Genotyping of BRCA1 and BRCA2 in the Italian family revealed the presence of two significant polymorphisms: the cancer-associated c.2612C>T SNP in BRCA1, and the c.-26G>A SNP in the BRCA2 gene, acting as an ovarian cancer risk modifier in carriers of deleterious BRCA1 mutations. Analysis of these SNPs in a genotypically-unrelated Polish family, characterized by prevalent breast neoplasms in carriers of the c.190T>C mutation, revealed a genetic profile consistent with the hypothetic role of both polymorphisms.
Collapse
Affiliation(s)
- P Willems
- Department of Basic Medical Sciences, Ghent University, Ghent, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, Diadema MR, Aurilio G, Santabarbara G, Ruggiero R, Belli C, Irlandese E, Fasano M, Ciardiello F, Procaccini E, Lo Schiavo F, Catalano G, De Vita F. Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer. Cancer Invest 2009; 26:250-5. [DOI: 10.1080/07357900701560612] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
43
|
|
44
|
|
45
|
Orditura M, Martinelli E, Galizia G, Vitiello F, Fasano M, Muto P, Ciardiello F, De Vita F. Chemoradiotherapy as adjuvant treatment of gastric cancer. Ann Oncol 2007; 18 Suppl 6:vi133-5. [PMID: 17591807 DOI: 10.1093/annonc/mdm242] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Historically, radiotherapy has been occasionally used in the treatment of gastric cancer. More recently, the results of INT-0116 trial have shown an improvement of disease-free and overall survival by chemoradiation with a significant impact on the management of this tumor. Based on these data, there has been an increasing interest in radiotherapy and its association with chemotherapy for patients with locoregional disease as a part of an adjuvant treatment after surgery in high-risk patients. However, many questions remain to evaluate; first of all the toxicity of this approach and its efficacy after adequate surgery.
Collapse
Affiliation(s)
- M Orditura
- Department of Medical Oncology, F. Magrassi & A. Lanzara, Second University of Naples School of Medicine, Naple, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies. J Neural Transm (Vienna) 2006; 113:769-74. [PMID: 16755381 DOI: 10.1007/s00702-005-0448-4] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2005] [Accepted: 12/20/2005] [Indexed: 01/12/2023]
Abstract
Human mesencephalic neuromelanin (NM) is characterized by an irregular, undefined structure, making its characterization by usual physico-chemical methodologies quite difficult. NM isolated from controls and from Parkinson's Disease (PD) patients was compared by high-resolution solid-state nuclear magnetic resonance (NMR). The pigment from PD patients appeared to be mainly composed of highly cross-linked, protease-resistant lipo-proteic material, with disappearance of melanin NMR resonances, suggesting melanin breakout due to oxidative stress conditions. Moreover, alpha-synuclein was detected in NM of PD patients and controls after cleavage of the melanin backbone under solubilizing conditions. NM stores iron ions as oxyhydroxide iron clusters containing thousands of iron atoms. Electron Paramagnetic Resonance (EPR) investigations and magnetic susceptibility measurements confirmed the occurrence of magnetic coupling among iron atoms, whereas in synthetic melanin the occurrence of isolated Fe(3+) ions was evident. NM from PD patients showed a lower total magnetization, possibly suggesting a progressive Fe migration from its storage environment (i.e., NM) to the cytosol.
Collapse
Affiliation(s)
- M Fasano
- Department of Structural and Functional Biology, and Centre of Neuroscience, University of Insubria, Busto Arsizio, VA, Italy.
| | | | | |
Collapse
|
47
|
Basso M, Giraudo S, Lopiano L, Bergamasco B, Bosticco E, Cinquepalmi A, Fasano M. Proteome analysis of mesencephalic tissues: evidence for Parkinson's disease. Neurol Sci 2004; 24:155-6. [PMID: 14598063 DOI: 10.1007/s10072-003-0106-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Proteome analysis is a powerful methodology to investigate protein expression in tissues involved in diseases not linked to particular genetic defects. To date, this technique has a limited number of applications in the field of neurodegenerative disorders. We decided therefore to investigate by this approach autoptic mesencephalic tissues of patients with idiopathic Parkinson's disease as well as control specimens from healthy subjects.
Collapse
Affiliation(s)
- M Basso
- Department of Structural and Functional Biology, and Center of Neuroscience, University of Insubria, via Alberto da Giussano 12, Busto Arsizio (VA), Italy
| | | | | | | | | | | | | |
Collapse
|
48
|
Bolzoni F, Giraudo S, Lopiano L, Bergamasco B, Fasano M, Crippa PR. Magnetic investigations of human mesencephalic neuromelanin. Biochim Biophys Acta 2002; 1586:210-8. [PMID: 11959462 DOI: 10.1016/s0925-4439(01)00099-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Pigmentation of neurons in substantia nigra is due to neuromelanin, a pigment that stores large amounts of iron. Human mesencephalic neuromelanin has been investigated by means of magnetic susceptibility measurements as a function of temperature. Magnetic measurements provide a physico-chemical characterization of the iron cluster buried in the organic melanin matrix and support the view that iron is not simply chelated, but rather is organized in a three-dimensional network. The paramagnetism of isolated iron ions is observed, in agreement with electron paramagnetic resonance spectroscopy. Furthermore, antiferromagnetic grains with a large size distribution function are present. These grains contain N spins coupled antiferromagnetically; however, N(1/2) spins are decoupled from the grain bulk and parallelly aligned. The latter subgrains are superparamagnetic with a blocking temperature ranging between 5 K and room temperature. This behavior has not been observed in synthetic melanin, where the paramagnetic contribution is strongly enhanced. Preliminary results on pigment isolated from patients affected by Parkinson's disease, a neurodegenerative pathology involving primarily pigmented neurons in substantia nigra pars compacta, show a lower total magnetization compared to control neuromelanin. The temperature behavior of zero field cooling and field cooling magnetizations is similar for both. The significant depletion of iron content in Parkinson's disease neuromelanin could indicate a progressive Fe migration from its storage environment to the cytosol.
Collapse
Affiliation(s)
- F Bolzoni
- MASPEC-CNR, Parco Area delle Scienze 37/A, 43010 Fontanini-Parma, Italy
| | | | | | | | | | | |
Collapse
|
49
|
Baroni S, Mattu M, Vannini A, Cipollone R, Aime S, Ascenzi P, Fasano M. Effect of ibuprofen and warfarin on the allosteric properties of haem-human serum albumin. A spectroscopic study. Eur J Biochem 2001; 268:6214-20. [PMID: 11733017 DOI: 10.1046/j.0014-2956.2001.02569.x] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Haem binding to human serum albumin (HSA) endows the protein with peculiar spectroscopic properties. Here, the effect of ibuprofen and warfarin on the spectroscopic properties of ferric haem-human serum albumin (ferric HSA-haem) and of ferrous nitrosylated haem-human serum albumin (ferrous HSA-haem-NO) is reported. Ferric HSA-haem is hexa-coordinated, the haem-iron atom being bonded to His105 and Tyr148. Upon drug binding to the warfarin primary site, the displacement of water molecules--buried in close proximity to the haem binding pocket--induces perturbation of the electronic absorbance properties of the chromophore without affecting the coordination number or the spin state of the haem-iron, and the quenching of the 1H-NMR relaxivity. Values of Kd for ibuprofen and warfarin binding to the warfarin primary site of ferric HSA-haem, corresponding to the ibuprofen secondary cleft, are 5.4 +/- 1.1 x 10(-4) m and 2.1 +/- 0.4 x 10(-5) m, respectively. The affinity of ibuprofen and warfarin for the warfarin primary cleft of ferric HSA-haem is lower than that reported for drug binding to haem-free HSA. Accordingly, the Kd value for haem binding to HSA increases from 1.3 +/- 0.2 x 10(-8) m in the absence of drugs to 1.5 +/- 0.2 x 10(-7) m in the presence of ibuprofen and warfarin. Ferrous HSA-haem-NO is a five-coordinated haem-iron system. Drug binding to the warfarin primary site of ferrous HSA-haem-NO induces the transition towards the six-coordinated haem-iron species, the haem-iron atom being bonded to His105. Remarkably, the ibuprofen primary cleft appears to be functionally and spectroscopically uncoupled from the haem site of HSA. Present results represent a clear-cut evidence for the drug-induced shift of allosteric equilibrium(a) of HSA.
Collapse
Affiliation(s)
- S Baroni
- Department of Chemistry IFM, University of Torino, Italy
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Hemalbumin [i.e., Fe(III)-protoporphyrin IX-human serum albumin; Fe(III)heme-HSA] is an important intermediate in the recovery of heme iron following hemolysis. Relaxometric data are consistent with the occurrence of a hexacoordinated high-spin Fe(III) center with no water in the inner coordination sphere. The relatively high relaxation enhancement observed for an aqueous solution of Fe(III)heme-HSA (r1p=4.8 mM(-1)s(-1) at 20 MHz, pH 7, and 25 C) is ascribed to the occurrence of a strong contribution from water molecules in the second coordination sphere. Structural analysis of the putative binding region has been performed by a Monte Carlo simulated annealing procedure, which allowed us to identify His105 and Tyr148 as axial ligands. The role of a tyrosinate as the sixth Fe(III)heme ligand is supported by the pH-dependent analysis. Interestingly, when Fe(III) is replaced by Mn(III), the occurrence of a fast exchanging water molecule at pH values close to neutrality is detected. As the pH is increased, the Mn(III) containing system behaves analogously to Fe(III)heme-HSA. At higher pH, the phenolate ligand is eventually displaced by OH- from both Fe(III) and Mn(III) centers. Support for the proposed bonding scheme has been gained also from competitive binding assays for the sixth coordination site by fluoride, azide, and imidazole ligands.
Collapse
Affiliation(s)
- M Fasano
- Dipartimento di Chimica IFM Università di Torino, Italy
| | | | | | | | | |
Collapse
|